

## HSV-2 gD (residues 266-384) Herpes Simplex Virus-2 glycoprotein D recombinant, *E. coli*

Cat. No.	Amount
PR-1110	100 µg

For *in vitro* use only  
Quality guaranteed for 12 months  
Store at -20°C

### Avoid freeze / thaw cycles

### Form

Liquid. Supplied in 25 mM Tris-HCl pH 7.2, 1 mM EDTA and 50% glycerol.

### Protein synonyms/aliases

Glycoprotein D precursor

### Molecular Weight

65.7 kDa

### Application

Recombinant rHSV-2 gD Antigen may be used in ELISA and Western blots, excellent for detection of HSV with minimal specificity problems.

### Specificity

Immunoreactive with sera of HSV-infected individuals.

### Purity

>95% by SDS-PAGE

### Description

The *E.coli* derived recombinant protein contains the HSV-2 gD immunodominant regions 266-394 amino acids, fused with 26 kDa GST-tag.

HSV-2-gD is purified by proprietary chromatographic techniques.

### Background

Glycoprotein D (gD) is essential for replication in cultured cells. Deletion mutants of the virus for the gD gene cannot penetrate into cells and neutralizing antibodies against the glycoprotein inhibit virus entry. Studies with antibodies raised against HSV gD indicate that the glycoprotein plays a role in the cell-to-cell fusion process.

### Selected References:

- Domingo *et al.* (2003) Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D. *Vaccine*. **21**:3565.
- Murata *et al.* (2002) Excretion of herpes simplex virus type 2 glycoprotein D into the culture medium. *J. Gen. Virol.* **83**:2791.
- Heineman *et al.* (1995) Immunization with recombinant varicellazoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. *J. Virol.* **69**:8109.
- Straus *et al.* (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. *Lancet*. **343**:1460.
- Nakao *et al.* (1994) Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein. *J. Infect. Dis.* **169**:787.
- Straus *et al.* (1993) Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. *J. Infect. Dis.* **167**:1045.